We are live on ! Find out more
OCUL icon

Ocular Therapeutix

79 hedge funds and large institutions have $100M invested in Ocular Therapeutix in 2019 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 22 increasing their positions, 21 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

555% more call options, than puts

Call options by funds: $1.22M | Put options by funds: $186K

110% more capital inflows, than outflows

Capital inflows: $14.1M | Capital outflows: $6.73M

31% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 13

5% more funds holding

Funds holding: 75 → 79 (+4)

3.5% more ownership

Funds ownership: 48.92% → 52.42% (+3.5%)

5% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

Holders
79
Holders Change
+4
Holders Change %
+5.33%
% of All Funds
1.55%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
17
Increased
22
Reduced
21
Closed
13
Calls
$1.22​M
Puts
$186​K
Net Calls
+$1.03​M
Net Calls Change
+$967​K

OCUL Hedge Fund Activity: Q4 2019 in Review

79 of the 5,095 institutional investors tracked by Wall St. Rank reported a position in Ocular Therapeutix (OCUL) for Q4 2019, worth a combined $100M — up 42% from $70.2M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new OCUL positions and 13 closed out — a net gain of 4 holders — while 22 added to existing stakes and 21 trimmed.

The largest buyer was Opaleye Management, adding an estimated $8.11M. The largest seller was Man Group, cutting an estimated $3.99M.

  • 79 institutional investors held Ocular Therapeutix (OCUL) as of Q4 2019, up from 75 in Q3 2019.
  • Funds reported $100M of Ocular Therapeutix stock for Q4 2019, up 42% quarter-over-quarter.
  • 17 funds opened new Ocular Therapeutix positions in Q4 2019 and 13 closed out, a net change of +4 holders.
  • The largest Ocular Therapeutix buyer in Q4 2019 was Opaleye Management, an estimated $8.11M added.
  • The largest Ocular Therapeutix seller in Q4 2019 was Man Group, an estimated $3.99M sold.

Based on aggregated 13F filings for Q4 2019.